Literature DB >> 24768944

Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells.

Annina Nickel1, Sonja C Stadler2.   

Abstract

The epithelial-to-mesenchymal transition (EMT) is a crucial process during normal development that allows dynamic and reversible shifts between epithelial and mesenchymal cell states. Cancer cells take advantage of the complex, interrelated cellular networks that regulate EMT to promote their migratory and invasive capabilities. During the past few years, evidence has accumulated that indicates that genetic mutations and changes to epigenetic mechanisms are key drivers of EMT in cancer cells. Recent studies have begun to shed light on the epigenetic reprogramming in cancer cells that enables them to switch from a noninvasive form to an invasive, metastatic form. The authors review the current knowledge of alterations of epigenetic machinery, including DNA methylation, histone modifications, nucleosome remodeling and expression of microRNAs, associated with EMT and tumor progression of breast cancer cells. Last, existing and upcoming drug therapies targeting epigenetic regulators and their potential benefit for developing novel treatment strategies are discussed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24768944     DOI: 10.1016/j.trsl.2014.04.001

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  20 in total

1.  Combined silencing of TGF-β2 and Snail genes inhibit epithelial-mesenchymal transition of retinal pigment epithelial cells under hypoxia.

Authors:  Zhuolei Feng; Ruishu Li; Huanqi Shi; Wenjiao Bi; Wenwen Hou; Xiaomei Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-21       Impact factor: 3.117

Review 2.  The role of EMT and MET in cancer dissemination.

Authors:  Jacqueline Banyard; Diane R Bielenberg
Journal:  Connect Tissue Res       Date:  2015-08-20       Impact factor: 3.417

Review 3.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

Review 4.  Epigenetic Determinants of Cancer.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-09-01       Impact factor: 10.005

5.  Mesenchymal stromal cells as regulators of anti-tumour immune response.

Authors:  Alessandro Poggi; M R Zocchi
Journal:  Indian J Med Res       Date:  2015-02       Impact factor: 2.375

Review 6.  From conventional therapy toward microRNA-based therapy in acute promyelocytic leukemia.

Authors:  Naeim Ehtesham; Mohammadreza Sharifi
Journal:  Adv Biomed Res       Date:  2016-11-28

Review 7.  Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment.

Authors:  Alessandro Poggi; Massimo Giuliani
Journal:  Vaccines (Basel)       Date:  2016-11-08

8.  Expression and significance of c-kit and epithelial-mesenchymal transition (EMT) molecules in thymic epithelial tumors (TETs).

Authors:  Zhigang Wu; Songtao Xue; Bin Zheng; Rongjin Ye; Guobing Xu; Shuliang Zhang; Taidui Zeng; Wei Zheng; Chun Chen
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

9.  Cullin3 promotes breast cancer cells metastasis and epithelial-mesenchymal transition by targeting BRMS1 for degradation.

Authors:  Xiongwei Huo; Suoni Li; Tingting Shi; Aili Suo; Zhiping Ruan; Hui Guo; Yu Yao
Journal:  Oncotarget       Date:  2015-12-08

Review 10.  Epithelial-Mesenchymal Transition and Breast Cancer.

Authors:  Yanyuan Wu; Marianna Sarkissyan; Jaydutt V Vadgama
Journal:  J Clin Med       Date:  2016-01-26       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.